Search results
Results from the WOW.Com Content Network
BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf. [5] [6] The B-Raf protein is involved in sending signals inside cells which are involved in directing ...
The structure of a plant cell wall is incredibly important for wound responses, as both protect the plant from pathogenic infections by preventing various molecules from entering the cell. [ 1 ] Plants are capable of activating innate immunity, by responding to wounding events with damage-associated Molecular Patterns (DAMPs). [ 1 ]
Encorafenib acts as an ATP-competitive RAF kinase inhibitor, decreasing ERK phosphorylation and down-regulation of CyclinD1. [10] This arrests the cell cycle in G1 phase, inducing senescence without apoptosis. [10] Therefore, it is only effective in melanomas with a BRAF mutation, which make up 50% of all melanomas. [11]
This page was last edited on 7 September 2014, at 19:11 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The plant immune system carries two interconnected tiers of receptors, one most frequently sensing molecules outside the cell and the other most frequently sensing molecules inside the cell. Both systems sense the intruder and respond by activating antimicrobial defenses in the infected cell and neighboring cells.
The signal that starts the MAPK/ERK pathway is the binding of extracellular mitogen to a cell surface receptor.This allows a Ras protein (a Small GTPase) to swap a GDP molecule for a GTP molecule, flipping the "on/off switch" of the pathway.
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
Vemurafenib causes programmed cell death in melanoma cell lines. [3] Vemurafenib interrupts the B-Raf/MEK step on the B-Raf/MEK/ERK pathway − if the B-Raf has the common V600E mutation. Vemurafenib only works in melanoma patients whose cancer has a V600E BRAF mutation (that is, at amino acid position number 600 on the B-Raf protein, the ...